Protai raises $12M for its AI-driven oncology drug discovery platformProtai can comprehensively map cancer in order to better predict which patients will respond to a given drug and discover novel drug targets. (Left to right) Protai founders Eran Seger, CEO, and Kirill Pevzner, CTO.(photo credit: David Garb)
